Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Aug;9(8):2437-2446.
doi: 10.21037/jtd.2017.07.06.

Statins may be beneficial for patients with pulmonary hypertension secondary to lung diseases

Ming-Zhou Zhang  1 , De-Hui Qian  2 , Jian-Cheng Xu  1 , Wei Yao  1 , Ye Fan  1 , Chang-Zheng Wang  1
Affiliations

Statins may be beneficial for patients with pulmonary hypertension secondary to lung diseases

Ming-Zhou Zhang et al. J Thorac Dis. 2017 Aug.

Abstract

Background: Previous animal studies and clinical trials report inconsistent findings regarding the role of statins in pulmonary hypertension (PH). Systematic reviews have shown no use of statins on pulmonary arterial hypertension (PAH). This is the first meta-analysis of randomized controlled trials (RCTs) determining the clinical impacts of statin therapy on patients with PH secondary to lung diseases.

Methods: Electronic databases and manual bibliographical searches were conducted. Eligible studies included RCTs of at least 3 months that evaluated statin therapy as compared with control in adult patients with PH due to pulmonary diseases. Statistical analyses were performed to calculate mean difference, relative risks (RRs), and 95% confidence intervals (CIs) using random-effect model.

Results: A total of 6 RCTs were identified and included in this study. Five trials reported the effects of statins in patients with both chronic obstructive pulmonary disease (COPD) and PH, and the remaining 1 was based on PH due to pneumoconiosis. We found that statin therapy was associated with increased 6-minute walk distance and reduced pulmonary artery systolic pressure. There was no observed difference in the incidence of death, drug withdrawal, and adverse event between statin and control group.

Conclusions: Our findings suggest that statins might be safe and beneficial for patients with PH due to chronic lung diseases. However, larger RCTs with more patients and longer observational duration are needed.

Keywords: Statin; chronic lung diseases; meta-analysis; pulmonary hypertension (PH).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Flowchart of study selection.
Figure 2
Figure 2
Forest plot evaluating the impact of statin therapy on 6-minute walk distance of patients with PH secondary to lung diseases (20,22,24).
Figure 3
Figure 3
Forest plot evaluating the impact of statin therapy on pulmonary artery systolic pressure of patients with PH secondary to lung diseases (20-23,25).
Figure 4
Figure 4
Forest plot evaluating the impact of statin therapy on mortality of patients with PH secondary to lung diseases (20,23,24).
Figure 5
Figure 5
Forest plot comparing statin group with control group for withdrawal (20-23).
Figure 6
Figure 6
Forest plot comparing statin group with control group for liver dysfunction (20-22,24).
Figure 7
Figure 7
Summary assessment of study quality (20-25).
See this image and copyright information in PMC

References

    1. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. Rev Esp Cardiol (Engl Ed) 2016;69:177. 10.1016/j.rec.2016.01.002 - DOI - PubMed
    1. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013;62:D34-41. 10.1016/j.jacc.2013.10.029 - DOI - PubMed
    1. Fraidenburg D, Yuan J. Current and future therapeutic targets for pulmonary arterial hypertension. High Alt Med Biol 2013;14:134-43. 10.1089/ham.2013.1007 - DOI - PubMed
    1. Young RP, Hopkins R, Eaton TE. Pharmacological actions of statins: potential utility in COPD. Eur Respir Rev 2009;18:222-32. 10.1183/09059180.00005309 - DOI - PubMed
    1. Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther 2003;99:95-112. 10.1016/S0163-7258(03)00055-X - DOI - PubMed